Temporal Artery and Dermal Fillers: Critical Safety Protocol

Anatomical Risk Assessment and Mandatory Safety Protocol

The temporal artery lies in the hypodermis, well below the dermis where safe filler injections should occur, requiring strict adherence to intradermal injection technique with visible papule formation to avoid the deeper vascular planes where the superficial temporal artery and its branches reside 1

Aspirate the needle prior to each injection to detect intravascular placement before filler administration, and use incremental injections rather than large boluses to minimize vascular compression and allow early detection of complications 1
Use exclusively intradermal placement with 30-gauge, 4mm length needles inserted at shallow angles with bevel facing upward, and create visible papules or wheals with blanching during injection to confirm proper intradermal placement and prove you are NOT in the hypodermis where major vessels exist 1
Inject in small volumes (0.2-0.5 mL per injection site) to minimize tissue distortion and vascular compression 2

Autologous platelet concentrates (APCs) provide rejuvenation effects including improvement in skin texture, color, and moisture without the prolonged vascular occlusion risk of cross-linked HA fillers, and offer superior biocompatibility and safety, reducing the risk of adverse effects and vascular occlusions compared to traditional fillers 3
APCs are particularly appropriate for fine lines and overall skin quality improvement rather than structural volumization, and the volumizing effect lasts only 3-4 months versus 6-18 months for HA fillers, but rejuvenation effects persist 2

Visual changes or eye pain represent ophthalmic artery involvement and constitute a medical emergency, requiring immediate recognition of arterial occlusion to prevent permanent complications 5
Inject hyaluronidase (0.1-0.2 mg/kg up to 10 mg diluted in 10 mL of 0.9% sodium chloride) intradermally at the affected site in case of suspected vascular occlusion 6

Avoid treating the temporal area when significant volumization is the primary goal; this region is better suited for superficial rejuvenation techniques, and do not use traditional HA fillers in the temporal region if APCs can achieve the desired aesthetic outcome, given the superior safety profile 1
Warn all patients about bruising, swelling, and tenderness as common treatment-related effects, and discuss the importance of prioritizing safety over maximal volumization in the temporal region 2
Explain that APCs may require more frequent retreatment but offer enhanced safety in this high-risk anatomical zone 3